proTAME

proTAME (pro-Tosyl-L-Arginine Methyl Ester) is a cell-permeable small molecule and a prodrug of TAME. It functions as an inhibitor of the anaphase-promoting complex/cyclosome (APC/C), a multi-subunit E3 ubiquitin ligase that is essential for cell cycle progression. Specifically, proTAME targets the APC/C co-activators Cdc20 and Cdh1 (Fzr), preventing the ubiquitination and subsequent degradation of key mitotic regulators such as cyclin B1 and securin. This inhibition leads to cell cycle arrest in metaphase and eventually triggers apoptosis. While primarily utilized as a chemical biology tool to study the mechanisms of mitosis, proTAME has been investigated in preclinical oncology research for its potential anti-tumor activity in various malignancies, including multiple myeloma, glioblastoma, and ovarian cancer, often in combination with other antimitotic agents. It is not currently developed by any pharmaceutical company for clinical use.

Other names

pro-Tosyl-L-Arginine Methyl Esterpro-TAMECAS 1362911-19-0CAS1362911-19-0CAS-1362911-19-0